Education
About Us
Working with TipRanks
Follow Us
Grail Inc (GRAL)
:GRAL
GRAL Stock Chart & Stats
$83.71
-$1.19(-6.66%)
At close: 4:00 PM EST
$83.71
-$1.19(-6.66%)
Day’s Range― - ―
52-Week Range$13.58 - $103.00
Previous CloseN/A
Volume371.20K
Average Volume (3M)1.19M
Market Cap
$2.89B
Enterprise Value$1.30B
Total Cash (Recent Filing)$602.75M
Total Debt (Recent Filing)$62.16M
Price to Earnings (P/E)―
Beta2.80
Next Earnings
Nov 12, 2025EPS Estimate
-3.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.18
Shares Outstanding36,047,800
10 Day Avg. Volume1,012,350
30 Day Avg. Volume1,192,614
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.23
Price to Sales (P/S)4.53
P/FCF Ratio-0.98
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue9.68
Enterprise Value/Gross Profit-178.34
Enterprise Value/Ebitda-2.77
Forecast
1Y Price Target
$60.86Price Target Upside-27.30% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-12.32
Revenue Forecast (FY)$143.93M
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionGRAIL announced a letter of intent with Samsung C&T to commercialize Galleri in key Asian markets, with an investment of $110 million.
Financial GrowthGRAIL raised $325.0 million in gross proceeds through a private placement, which will add over $400 million in cash to GRAL's balance sheet.
Market PerformanceGRAL's shares have appreciated over 80% year-to-date, indicating strong market performance and investor interest.
Bears Say
Cost ConcernsImaging may increase the total cost of screening, which would likely negatively impact the acceptance of Galleri by the UK's NHS.
Regulatory UncertaintyAlthough the data improved from PATHFINDER 1, it is unclear if it will be adequate for FDA approval.
Technological RisksThere are inherent risks associated with novel technologies from a regulatory and reimbursement pathway perspective.
GRAIL Inc News
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $13.58 and its highest was $103.00 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $2.89B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Nov 12, 2025 which is in 3 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on Aug 12, 2025. The company reported -$3.18 earnings per share for the quarter, beating the consensus estimate of -$3.568 by $0.388.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Overvalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -3.35.
How many shares outstanding does Grail Inc have?
Grail Inc has 36,047,800 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$3.18 in its last earnings report, beating expectations of -$3.568. Following the earnings report the stock price went up 1.131%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in GRAL
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.86 (-27.30% Downside)
$60.86 (-27.30% Downside)
Blogger Sentiment
Bullish
GRAL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 535.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 28.5%
Last 30 Days ▲ 28.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
432.88%
12-Months-Change
Fundamentals
Return on Equity
-17.68%
Trailing 12-Months
Asset Growth
-17.34%
Trailing 12-Months
Company Description
Grail Inc
GRAIL Inc. is a biotechnology company focused on the early detection of cancer through its innovative multi-cancer early detection (MCED) blood tests. The company operates primarily in the healthcare sector, leveraging advanced genomic technologies and data analytics to develop its core products. GRAIL aims to transform cancer screening by providing tests that can detect multiple types of cancer at their earliest stages, thereby improving patient outcomes and enabling timely intervention.
GRAL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments in commercial growth, clinical trial results, and financial management, alongside operational challenges and high net loss. The positive aspects, including strong revenue growth and clinical trial outcomes, slightly outweigh the lowlights, indicating a cautiously optimistic outlook.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$60.86
▼(-27.30% Downside)
Technical Analysis
Ownership Overview
13.51% Insiders
14.32% Mutual Funds
0.55% Other Institutional Investors
59.77% Public Companies and
Individual Investors